China’s ASK Buys 5 Percent Stake In New Zealand’s Living Cell Tech
This article was originally published in PharmAsia News
Executive Summary
China's Jiangsu Aosaikang Pharmaceutical (ASK) bought a 5 percent stake in New Zealand's Living Cell Technologies
China's Jiangsu Aosaikang Pharmaceutical (ASK) bought a 5 percent stake in New Zealand's Living Cell Technologies. The New Zealand company implants pig tissues into diabetics to enhance insulin production. The deal with the Chinese company, a private drug-research firm, also gives ASK control of the LCT technology in China. For its part, LCT plans to use the U.S $2.2 million investment to take Diabecell through additional development and clinical trials. (Click here for more) "China Buys Into NZ Diabetes Technology" - New Zealand Herald (2/1/11) |